bs-13270R **[Primary Antibody]**

GALNT10 Rabbit pAb

www.bioss.com.cn
sales@bioss.com.cn
techsupport@bioss.com.cn
400-901-9800

DATASHEET

Host: Rabbit **Isotype:** IgG

Clonality: Polyclonal

GeneID: 55568 **SWISS:** Q86SR1

Target: GALNT10

Immunogen: KLH conjugated synthetic peptide derived from human GALNT10/GalNAc-T10: 151-250/603.

Purification: affinity purified by Protein A

Concentration: 1mg/ml

Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background: The UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase (GalNAc-T) family of enzymes are substrate-specific proteins that catalyze the transfer of GalNAc (N-acetylgalactosaminyl) to serine and threonine residues of various proteins, thereby initiating mucin-type O-linked glycosylation in the Golgi apparatus. GalNAc-T10 (Polypeptide N-acetylgalactosaminyltransferase 10), also known as UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 10, is a 603 amino acid single-pass type II membrane protein that prefers Muc5Ac and EA2 peptide substrates. The N-terminal domain is involved in substrate binding and manganese coordination, while the C-terminal domain is involved in UDP-Gal binding and catalytic reaction. GalNAc-T10 is widely expressed, with highest levels found in small intestine. There are four isoforms of GalNAc-T10 that are produced as a result of alternative splicing events.

Applications: **WB** (1:500-2000)

Reactivity: Human (predicted: Mouse, Rat, Rabbit, Pig, Cow, Chicken, Horse)

Predicted MW.: 69 kDa

Subcellular Location: Cell membrane ,Cytoplasm

VALIDATION IMAGES



Sample: MCF-7 (human)Cell Lysate at 40 ug Hela (human)Cell Lysate at 40 ug Primary: Anti-GALN10(bs-13270R) at 1/300 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 69 kD Observed band size: 69 kD

SELECTED CITATIONS

- **[IF=3.743]** Hou C et al. TMT-based proteomics analysis of the anti-hepatocellular carcinoma effect of combined dihydroartemisinin and sorafenib. Biomed Pharmacother. 2020 Jun;126:109862. WB ;human. 32120157